ACETO Corp (ACET) Declares $0.06 Quarterly Dividend; 0.9% Yield
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
ACETO Corp (ACET) Announces U.S. Launch of Generic Patanol
December 7, 2015 2:45 PM ESTACETO Corporation (NASDAQ: ACET) announced that Rising Pharmaceuticals, Inc., its finished dosage form generics subsidiary, is launching Olopatadine Hydrochloride 0.1% Ophthalmic Solution, an FDA-approved generic version of Alcon Inc.'s Patanol.
According to IMS Health data, U.S. market sales for Olopatadine Hydrochloride... More
